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ABSTRACT 
G protein-coupled oestrogen receptor 1 (GPER), also called G protein-coupled receptor 30 
(GPR30), is attracting considerable attention for its potential role in breast cancer 
development and progression. Activation by oestrogen (17β-oestradiol; E2) initiates short 
term, non-genomic, signalling events both in vitro and in vivo. Published literature on the 
prognostic value of GPER protein expression in breast cancer indicates that further 
assessment is warranted. We show, using immunohistochemistry on a large cohort of primary 
invasive breast cancer patients (n=1245), that low protein expression of GPER is not only 
significantly associated with clinicopathological and molecular features of aggressive 
behaviour but also significantly associated with adverse survival of breast cancer patients. 
Furthermore, assessment of GPER mRNA levels in the METABRIC cohort (n=1980) 
demonstrates that low GPER mRNA expression is significantly associated with adverse survival 
of breast cancer patients. Using artificial neural networks, genes associated with GPER mRNA 
expression were identified; these included notch-4 and jagged-1. These results support the 
prognostic value for determination of GPER expression in breast cancer. 
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INTRODUCTION 
Breast cancer is the most common cancer in women, with over 1.7 million cases diagnosed 
worldwide in 2012 [1]. The female sex hormone, oestrogen (17β-oestradiol; E2), has an 
important role in breast cancer development and progression, with effects mediated through 
nuclear oestrogen receptors (ER and ERβ) which act directly as transcription factors to 
regulate the expression of genes able to alter cell survival and growth. 
G protein-coupled oestrogen receptor 1 (GPER) or G protein-coupled receptor 30 (GPR30) is 
a G protein-coupled receptor first cloned in 1996 [2] and first described in breast cancer in 
the ER positive MCF-7 cell line [3]. GPER has a potential role in breast cancer although 
controversies exist over its subcellular localisation, and mechanism of receptor activation [4-
6]. GPER has been shown to bind E2 to initiate short term, non-genomic, signalling events 
both in vitro [7-9] and in vivo [10]. Expression of GPER has also been shown to be associated 
with ER expression and status in a number of studies [11] and to attenuate the growth of ER 
positive breast cancer [11]. Tamoxifen has been shown to act as a GPER agonist, and GPER 
has been implicated in tamoxifen resistance via its upregulation in a tamoxifen resistant 
breast cancer cell line which results in the activation of epidermal growth factor receptor 
(EGFR) [12].  
GPER activation upregulates interleukin-1 receptor-1 (IL1R1) expression on breast cancer cells 
and interleukin (IL)-1 expression on cancer associated fibroblasts in a signalling loop to 
encourage invasive features of breast cancer [13]. GPER also supresses migration and 
angiogenesis of ER negative triple negative breast cancer by inhibiting nuclear factor (NF)-
κB/interleukin (IL)-6 signals [14]. 
GPER expression in breast cancer has been assessed in a number of studies; however, these 
have proved ambiguous. High GPER protein expression is associated with increased distant 
disease free survival in ER-positive lymph node negative disease [15], presence of metastasis 
[16] and adverse relapse free survival of patients treated with tamoxifen [17]. GPER mRNA 
expression is significantly lower in tumour tissue in comparison to normal tissue, indicating 
that GPER acts as a tumour suppressor [18, 19]. Recently, a large assessment of GPER mRNA 
expression in 781 primary breast tumours demonstrated that high GPER expression is 
associated with favourable overall survival and that GPER silencing may be due to hyper-
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methylation of the flanking regions of  the upstream CpG island [19]. However a smaller study 
of 167 breast cancer patients showed no association between mRNA expression and patient 
survival [20].  
 
This study sought to investigate the expression levels of GPER mRNA and protein in large well 
characterised cohorts of breast cancer patients and assess for association with survival. 
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RESULTS 
GPER protein staining location and frequency 
GPER expression was observed in both the nucleus and the cytoplasm of tumour cells. 
Staining varied from weak to intense, with heterogeneity observed between adjacent tumour 
cells. Representative photomicrographs are shown in Figure 1. Cytoplasmic GPER expression 
had a median H-score of 10 and ranged from 0-290. Nuclear GPER expression had a median 
score of 0 and ranged from 0-100. X-tile was used to generate cut points for assessment based 
on breast cancer specific survival with a cut point of 25 for cytoplasmic GPER expression with 
73.6% of cases (916/1244) demonstrating low expression; nuclear GPER expression had a cut 
point of 5 with 70.0% of cases (869/1241) demonstrating low expression. A proportion of 
cores within the tissue microarray could not be assessed as they were missing or cores had 
insufficient tumour cells. 
Relationship between GPER protein expression and clinicopathological variables 
High nuclear GPER expression was significantly associated with smaller tumours (χ2=22.5; 
d.f.=1; P<0.001), lower tumour grade (χ2=23.6; d.f.=2; P<0.001), lower NPI value (χ2=22.0; 
d.f.=2; P<0.001), ER positive tumours (χ2=4.8; d.f.=1; P=0.029); and with tumour stage (χ2=7.5; 
d.f.=2; P=0.024) (Table 1). No significant associations between cytoplasmic GPER expression 
and clinicopathological variables were observed (Table 1).  
Association between GPER protein expression and survival 
Low expression of cytoplasmic GPER was significantly associated with adverse breast cancer-
specific survival (P=0.002) (Figure 2A). In multivariate Cox regression cytoplasmic GPER 
expression remained significantly associated (P=0.023) with breast cancer survival when 
including the potential confounding factors of tumour size, tumour stage and grade, NPI 
value, ER, PgR and HER2 status and Lymph node status (with individual Kaplan–Meier 
statistics of P<0.001, P<0.001, P<0.001, P<0.001, P=0.002, P<0.001, P<0.001, P<0.001 
respectively) (Table 2). Expression of GPER in the nucleus was not significantly associated with 
breast cancer specific-survival (P=0.067) (Figure 2B). In addition to disease specific survival, 
cytoplasmic expression of GPER was significantly associated with adverse relapse free interval 
(P=0.023), but not nuclear GPER expression (P=0.057) (Figure 4A and 4B).   
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Interestingly, low expression of cytoplasmic GPER was significantly associated with adverse 
survival of patients who received endocrine therapy (P=0.003) (Figure 3B); whereas no 
association was observed in breast cancer-specific survival in patients who did not receive 
endocrine therapy (P=0.205) (Figure 3A). There was no difference observed in breast cancer 
specific survival of patients receiving endocrine therapy dependent upon nuclear GPER 
expression. 
GPER mRNA expression and clinicopathological variables 
Data was available for two GPER probes in the METABRIC dataset probe 1 (ILMN_1795298) 
and probe 2 (ILMN_2384056). Both were assessed independently for associations with 
clinicopathological variables and patient survival (Table 3) and were categorised into low and 
high groups using X-tile. Both GPER probe 1 and probe 2 demonstrated that low GPER 
expression were associated with basal and HER2 PAM50 subtype (χ2=207.4; d.f.=4; P<0.001 
and χ2=177.5; d.f.=4; P<0.001 respectively). Low GPER mRNA expression was associated with 
P53 mutation status (χ2=19.7; d.f.=1; P<0.001 and χ2=33.4; d.f.=1; P<0.001 for probe 1 and 2 
respectively), stage (χ2=11.4; d.f.=4; P=0.023 and χ2=11.1; d.f.=4; P=0.025 for probe 1 and 2 
respectively), larger tumour size (χ2=16.2; d.f.=1; P<0.001 and χ2=16.9; d.f.=1; P<0.001 for 
probe 1 and 2 respectively), higher tumour grade (χ2=83.0; d.f.=2; P<0.001 and χ2=87.3; d.f.=2; 
P<0.001 for probe 1 and 2 respectively) and ER negative tumours (χ2=119.1; d.f.=1; P<0.001 
and χ2=130.3; d.f.=1; P<0.001 for probe 1 and 2 respectively). 
Association between GPER mRNA expression and patient survival 
Low GPER probe 1 and probe 2 mRNA expression was significantly associated with adverse 
overall survival of the breast cancer cohort; (P=0.004) and (P=0.001) respectively (Figure 5A 
and 5B). 
Comparison between GPER mRNA and protein expression 
There were 194 tumours in this study that were assessed for GPER protein expression and for 
GPER mRNA expression as part of the METABRIC cohort. Cytoplasmic expression of GPER was 
not correlated with GPER probe 1 or probe 2 mRNA expression (P=0.824, R2=-0.016 and 
P=0.868, R2=0.012 respectively. Nuclear GPER expression was not correlated with GPER probe 
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1 mRNA expression (P=0.079, R2=-0.126), but was correlated with GPER probe 2 mRNA 
expression (P=0.024, R2=0.162). 
Expression profiling 
The gene expression data was analysed using an artificial neural network approach that uses 
a machine learning based data mining algorithm [21]. A rank order of all the genes was 
produced based on the minimum average root mean squared error. The top 200 transcripts 
were selected for GPER probe 1 and probe 2, and 84 common transcripts were identified. The 
top 20 unique transcripts include myomesin 1, ribosomal protein L39 like, vinexin beta and 
high density lipoprotein binding protein (Table 4). Some of these transcripts were assessed 
further using an ANOVA based approach to determine their relationship with GPER mRNA 
expression. A positive association was observed between both GPER probes and notch-4 
(both P<0.001), jagged-1 (both P<0.001), claudin-5 (both P<0.001), CD34 (both P<0.001) and 
adenylate cyclase 4 (both P<0.001). 
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DISCUSSION 
In this study, we describe how GPER protein and mRNA expression levels at the time of 
surgery are associated with breast cancer patient survival and various clinicopathological 
variables. Low cytoplasmic GPER protein expression was significantly associated with adverse 
breast cancer specific survival (P=0.002) and remained so in multivariate analysis including 
various potentially confounding factors, such as ER status. GPER expression within the nucleus 
was not associated with patient survival. It would be interesting to hypothesise over the 
importance of non-genomic actions of GPER; however, this study assessed expression of GPER 
with no measure of its activity. 
Previously published studies have investigated GPER expression in patient samples to show a 
number of associations with clinicopathological variables, however the results from these 
have not always been in agreement. One of the largest studies to date investigated 981 
primary invasive breast carcinomas, including investigation of nuclear and cytoplasmic GPER 
staining and is in consensus with the current findings. This study demonstrated that low 
expression of GPER was significantly associated with adverse patient survival and that there 
was no association with nuclear GPER expression and patient survival; this could not be 
demonstrated in multivariate analysis and was not described in any patient subset [22]. No 
data for systemic therapy was available for the patient cohort, so this was not assessed. Other 
studies have also investigated GPER expression, including a study of 481 breast cancer 
patients split into two cohorts of pre and post-menopausal women, which showed that high 
GPER protein expression was associated with increased distant disease free survival of ER 
positive lymph node negative and stage II breast cancer, but did not assess associations with 
disease specific survival [15]. A study investigating 321 invasive and 40 intraductal breast 
tumours showed associations between GPER expression with tumour size and the presence 
of distant metastasis, but also did not assess for associations with disease specific survival 
[16]. Furthermore GPER has been assessed in 323 breast cancer patients with a validation 
cohort of 103 patients to show associations between GPER expression and lymph node status, 
and HER2 status; this study also demonstrated an association between high GPER expression 
and adverse relapse free survival but no association was observed for overall survival [17].  
Interestingly, we were also able to demonstrate that low cytoplasmic GPER expression was 
associated with adverse survival in breast cancer patients treated with endocrine therapy, 
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mainly in the adjuvant setting. This is in disagreement with a previous study that 
demonstrated that high GPER expression was associated with adverse relapse free survival of 
breast cancer patients treated with tamoxifen but did not describe associations with breast 
cancer specific survival [17].  
Associations between GPER protein expression and HER2 status, amongst other 
clinicopathological variables, have been described in some studies, however; there was no 
association between cytoplasmic or nuclear GPER expression with HER2 in this study. A 
number of associations between clinicopathological variables and nuclear GPER expression 
were observed, but none when expression was assessed within the cytoplasm. It is unclear as 
to the function of nuclear GPER expression, there are limited reports of nuclear expression in 
vitro, with studies demonstrating concentration of GPER in a compartment in close proximity 
to the nucleus [23], and direct nuclear localisation in breast cancer associated fibroblasts 
driven by changes in N-linked glycosylation [24]. 
We also investigated the expression of GPER mRNA in the METABRIC cohort. Low GPER 
expression was significantly associated with adverse survival of breast cancer patients. Two 
probes representing GPER were identified and assessed, probe 1 (ILMN_1795298) and probe 
2 (ILMN_2384056), both located in the 3’ untranslated region. GPER mRNA expression was 
associated with various clinicopathological variables, the strongest association being with 
PAM50 subtype, ER status and tumour grade. 
Other studies investigating GPER mRNA expression in breast cancer have done so in 
comparison to normal mammary tissue to demonstrate lower staining in tumour tissue [25]. 
One of the largest studies to date reported GPER expression in 84 normal breast tissues and 
781 primary breast tumours using TCGA RNAseq data accessed through the UCSC Cancer 
Genomics Browser; they demonstrated that GPER expression is lower in primary tumours 
than normal breast tissues and that higher GPER expression in breast cancer patients was 
associated with increased survival, which is in agreement with our findings [19]. 
We performed artificial neural network analysis of transcriptomic array data to identify genes 
strongly associated with GPER expression. Interestingly, some well investigated proteins 
associated with breast cancer were identified, including notch-4, jagged-1 and CD34. 
Furthermore; links between some of the genes identified as associated with GPER expression 
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have previously been described. The use of a GPER agonists has been shown to increase the 
levels of claudin-5 in the ischemic CA1 in vivo [26] and also increased levels of CD34 in mouse 
xenograft models of breast cancer [27]. GPER has also been shown to be capable of 
stimulating adenylyl cyclase activity [28]. Although a direct link with notch-4 has not been 
described, GPER has been shown to engage notch-1 signaling to alter gene expression and 
cell migration in breast cancer in vitro [29].  
In summary, we have been able to demonstrate that low GPER protein and mRNA expression 
is associated with adverse survival in a large cohort of breast cancer patients. These findings 
suggest that GPER may have prognostic potential and may have utility as a therapeutic target 
and warrant further investigation in multi-centre studies. 
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MATERIALS AND METHODS 
Immunohistochemistry patient cohort 
This study is reported according to reporting recommendations for tumour marker prognostic 
studies (REMARK) criteria [30]. Ethical approval for this study was granted by Nottingham 
Research Ethics Committee 2, under the title ‘Development of a molecular genetic 
classification of breast cancer’ (C202313). 1245 early stage invasive breast cancer patients 
treated at Nottingham University Hospitals between 1987 and 1998 were stained for GPER 
protein expression. All specimens have been handled according to The Royal College of 
Pathologists ‘Pathology reporting of breast disease in surgical excision specimens 
incorporating the dataset for histological reporting of breast cancer’, with specimens sent 
immediately to the pathological laboratory after surgical resection and pre-dissected/incised. 
If incision of the fresh specimen was not possible, it was immediately placed in an adequate 
volume of fixative, at least twice that of the specimen.  
All patients were managed in a standard manner, where all patients underwent a mastectomy 
or wide local excision, as decided by disease characteristics or patient choice, followed by 
radiotherapy if indicated. Patients received systemic adjuvant treatment on the basis of 
Nottingham Prognostic index (NPI), ER, and menopausal status. Patients with an NPI score 
less than 3.4 did not receive adjuvant treatment and patients with an NPI score of 3.4 were 
candidates for CMF chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil) if 
they were ER negative or premenopausal; and hormonal therapy if they were ER positive. 
Breast cancer specific survival was calculated as the time interval between primary surgery 
and death resultant from breast cancer. 
Median survival for the cohort was 204 months as estimated by the reverse Kaplan-Meier 
method. The median age for this cohort was 55 years, ranging from 24 to 72. In this cohort 
16.1% of patients (199/1238) had grade one tumours, 33.6% (416/1238) had grade two 
tumours and 50.3% (623/1238) had grade three tumours. 60.9% of patients (754/1238) had 
stage one tumours, 30.1% of patients (373/1238) had stage two tumours and 9.0% of patients 
(111/1238) had stage 3 tumours. 72.9% of patients (878/1205) were ER positive, 56.7% of 
patients (665/1173) were progesterone receptor (PgR) positive and 13.6% (165/1213) of 
patients were HER2 positive. 58.2% (725/1245) were invasive ductal carcinomas, 17.3% 
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(215/1245) were tubular mixed, 5.9% (74/1245) were classic lobular all other subcategories 
accounted for less than 5% of the studied cohort. 
Immunohistochemistry 
Immunohistochemistry was performed as previously described using a Novolink Polymer 
Detection kit (Leica) according to the manufacturers’ instructions [31]. In brief, slides were 
deparaffinised in xylene, followed by rehydration in ethanol and water. Antigen retrieval was 
performed in 0.01molL-1 sodium citrate buffer (pH6.0) in a microwave for 10 minutes at 
750W and 10 minutes at 450W. Tissue was treated with peroxidase block, washed with Tris-
buffered saline (TBS), and then treated with protein block solution. Rabbit polyclonal anti-
GPER (Thermo Scientific (PA5-28647)) was used as primary antibody diluted 1:100 and was 
incubated on the tissue for one hour. Tissue was washed with TBS prior to the application of 
post primary solution, tissue was subsequently washed with TBS and then Novolink polymer 
solution was applied. Immunohistochemical reactions were developed using 3,3’ 
diaminobenzidine as the chromogenic substrate and tissue was counterstained with 
haematoxylin. Tissue was dehydrated in ethanol and fixed in xylene. Positive and negative 
controls were included with each staining run and were comprised of breast tumour 
composite sections comprising grade 1 and 2 early stage invasive tumour; negative controls 
had primary antibody omitted from each staining run (supplementary information).  
Gene expression patient cohort 
Details of the Molecuar Taxonomy of Breast Cancer International Consortium (METABRIC) 
data set (n=1980) data set have been published elsewhere [32]. For genomic and 
transcriptional profiling, DNA and RNA were isolated from samples and hybridised to the 
Affymetrix SNP 6.0 and Illumina HT-12 v3 platforms as described by Curtis et al (2012) [32]. In 
the METABRIC cohort ER positive and/or lymph node negative patients did not receive 
adjuvant chemotherapy; ER negative and/or lymph node positive patients received adjuvant 
chemotherapy.  
Immunohistochemistry scoring and statistical analyses 
Assessment of immunohistochemical staining was conducted at 200x magnification following 
high resolution scanning using a Nanozoomer Digital Pathology Scanner (Hamamatsu 
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Photonics). Staining in the cytoplasm was assessed using a semi-quantitative 
immunohistochemical H score; where staining intensity was assessed as none (0), weak (1), 
medium (2) or strong (3) over the percentage area of each staining intensity. Nuclear staining 
was assessed as the percentage of nuclei with any percentage intensity of staining. Greater 
than 30% of cores were double assessed, with both assessors blinded to clinical outcome and 
each other’s scores. The single measure intraclass correlation coefficient were above 0.7, 
indicating good concordance between scorers. 
Statistical analysis was performed using IBM SPSS Statistics (version 24). Data was stratified 
based on breast cancer specific survival using X-Tile software [33]. All differences were 
deemed statistically significant at the level of P<0.05. The Pearson χ2 test of association was 
used to determine the relationship between categorised protein expression and 
clinicopathological variables. Survival curves were plotted according to the Kaplan-Meier 
method with significance determined using the log-rank test. The primary endpoint of this 
study was to determine if GPER expression is associated with breast cancer specific survival. 
Identification of genes associated with GPER expression 
To further understand the molecular function of GPER in human breast cancer, the METABRIC 
series was analysed using a supervised artificial neural network. GPER expression was used as 
the supervising variable as described by Abdel-Fatah et al. [21]. The artificial neural network 
was conducted with multi-layer perceptron architecture and sigmoidal transfer function, 
where weights were updated by a back propagation algorithm. The top 200 genes associated 
with GPER mRNA expression for probe 1 and probe 2 were used for further analysis. 
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Figure and table legends 
Table 1: Associations between the expression of cytoplasmic and nuclear GPER determined 
by immunohistochemistry with clinicopathological variables. The P values are resultant from 
Pearson χ2 test of association. ER is oestrogen receptor and PgR is progesterone receptor. 
Table 2: Cox proportional hazards analysis for overall survival for cytoplasmic GPER 
expression in breast cancer. Exp(B) is used to denote hazard ratio and 95% CI is used to denote 
95% confidence interval. 
Table 3: Associations between the GPER mRNA expressions in the METABRIC cohort with 
clinicopathological variables. The P values are resultant from Pearson χ2 test of association. 
ER is oestrogen receptor and PgR is progesterone receptor.  
Table 4: The top 20 unique transcripts identified using artificial neural networks as associated 
with GPER mRNA expression in the METABRIC series. 
Figure 1: Representative photomicrographs following immunohistochemical staining of A: 
negative nuclear and cytoplasmic GPER staining; B: positive nuclear staining; C: positive 
cytoplasmic staining in breast cancer specimens. Photomicrographs are shown at 100x 
magnification with 200x magnification inset box where the scale bar represents 100µm. 
Figure 2: Kaplan-Meier analysis of breast cancer specific survival showing the impact of low 
(grey line) and high (black line) GPER protein expression within the cytoplasm (A) or the 
nucleus (B) with significance determined using the log-rank test. The numbers shown below 
the Kaplan-Meier survival curves are the number of patients at risk at the specified month.  
Figure 3: Kaplan-Meier analysis of breast cancer specific survival showing the impact of low 
(grey line) and high (black line) GPER protein expression within the cytoplasm in patients who 
did not receive endocrine therapy (A) or patients that did receive endocrine therapy (B) with 
significance determined using the log-rank test. The numbers shown below the Kaplan-Meier 
survival curves are the number of patients at risk at the specified month.  
Figure 4: Kaplan-Meier analysis of relapse free survival showing the impact of low (grey line) 
and high (black line) GPER protein expression within the cytoplasm (A) or the nucleus (B) with 
significance determined using the log-rank test. 
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Figure 5: Kaplan-Meier analysis of overall survival showing the impact of low (grey line) and 
high (black line) GPER mRNA expression with probe 1 (A) or probe 2 (B) with significance 
determined using the log-rank test. The numbers shown below the Kaplan-Meier survival 
curves are the number of patients at risk at the specified month.  
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